OverviewSuggest Edit
Pfenex is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins. The Company has developed a high-quality protein production and bioanalytic technology platform approach that allows them to create biosimilars in a highly efficient manner.
Pfenex's patented protein production platform, Pfenex Expression Technology, enables its ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enable the rapid delivery of protein products into clinical development and commercialization.
| Type | Public | |
| Founded | 2009 | |
| HQ | San Diego, US | Map |
| Website | pfenex.com | |
| Employee Ratings | More |
Recent NewsAll News
- Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.
- Pfenex to Announce Second Quarter Financial Results on August 6
- Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
Key People/Management at Pfenex
Martin Brenner
Chief Scientific Officer
Shawn Scranton
Chief Operating Officer
Patrick K. Lucy
Chief Business Officer
Eef Schimmelpennink
Chief Executive Officer, President, and Secretary
Jason Grenfell-Gardner
M.B.A, Chairman
Pfenex Office Locations
Pfenex has an office in San Diego
San Diego, US (HQ)
10790 Roselle St
Pfenex Financials and Metrics
Pfenex Revenue
Pfenex's revenue was reported to be $50.33 m in FY, 2019
| USD | |
|---|---|
Revenue (Q2, 2020) | 781.0k |
Gross profit (Q2, 2020) | 101.0k |
Gross profit margin (Q2, 2020), % | 12.9% |
Net income (Q2, 2020) | (10.3m) |
EBIT (Q2, 2020) | (10.3m) |
Market capitalization (14-Sept-2020) | 435.9m |
Closing stock price (14-Sept-2020) | 12.7 |
Cash (30-Jun-2020) | 61.0m |
Pfenex's current market capitalization is $435.9 m.
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.3m | 2.8m | 2.0m | 2.3m | 2.1m | 2.8m | 3.1m | 48.8m | 2.8m | 3.0m | 5.0m | 3.7m | 4.2m | 3.6m | 10.4m | 2.8m | 15.2m | 682.0k | 781.0k |
Cost of goods sold | 2.5m | 1.6m | 1.3m | 921.0k | 682.0k | 1.3m | 1.4m | 1.3m | 810.0k | 905.0k | 1.8m | 1.5m | 924.0k | 1.5m | 1.6m | 1.1m | 1.1m | 340.0k | 680.0k |
Gross profit | 722.0k | 1.2m | 667.0k | 1.4m | 1.4m | 1.5m | 1.7m | 47.5m | 2.0m | 2.1m | 3.3m | 2.2m | 3.3m | 2.1m | 8.8m | 1.7m | 14.1m | 342.0k | 101.0k |
Gross profit Margin, % | 22% | 44% | 34% | 60% | 67% | 54% | 54% | 97% | 71% | 70% | 65% | 59% | 78% | 59% | 85% | 60% | 93% | 50% | 13% |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 3.9m | 51.5m | 92.0m | 123.0m | 115.9m | 96.5m | 89.6m | 93.6m | 70.2m | 59.9m | 48.4m | 47.1m | 80.2m | 67.8m | 45.8m | 41.6m | 32.5m | 65.6m | 61.0m |
Accounts Receivable | 1.4m | 1.8m | |||||||||||||||||
Prepaid Expenses | 1.5m | 426.0k | 2.1m | 2.3m | 2.0m | 2.1m | 3.1m | 2.3m | 1.8m | 1.3m | 1.7m | 1.6m | 1.7m | 2.0m | 2.1m | 1.7m | 2.4m | ||
Inventories | 18.0k | 24.0k | 21.0k | 31.0k | 25.0k |
Annual
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.7m) | (6.2m) | (6.0m) | (12.0m) | (19.5m) | (8.2m) | (18.4m) | 16.1m | (10.0m) | (22.4m) | (31.2m) | (11.0m) | (22.1m) | (32.8m) | (3.7m) | (11.3m) | (8.2m) | (10.2m) | (20.5m) |
Depreciation and Amortization | 498.0k | 746.0k | 259.0k | 523.0k | 792.0k | 282.0k | 575.0k | 886.0k | 319.0k | 657.0k | 1.0m | 407.0k | 824.0k | 1.2m | 444.0k | 892.0k | 1.4m | 466.0k | 957.0k |
Inventories | 8.0k | 2.0k | 2.0k | (8.0k) | (2.0k) | ||||||||||||||
Accounts Payable | (677.0k) | (324.0k) | 685.0k | 598.0k | 273.0k | 202.0k | 562.0k | 1.0m | (79.0k) | 475.0k | 307.0k | (333.0k) | 630.0k | (560.0k) | (822.0k) | (1.5m) | 100.0k | (275.0k) | 1.5m |
| USD | Q2, 2014 |
|---|---|
Financial Leverage | -0.3 x |
Pfenex Cybersecurity Score
Pfenex Online and Social Media Presence
4.17k Twitter followers
Pfenex has 4.17k Twitter Followers. The number of followers has increased 0.1% month over month and decreased 1.4% quarter over quarter
Pfenex's Trends
Pfenex News and Updates
September 11, 2020
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management. If you are a CBMG investor, and would like...
August 12, 2020
SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.
NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by...
July 20, 2020
Pfenex to Announce Second Quarter Financial Results on August 6
SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its fin…
October 07, 2019
Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
NEW YORK, Oct. 7, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, KO, MTCH, PFNX, and RNG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
October 07, 2019
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval
March 27, 2019
Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Eef Schimmelpennink, …
Pfenex Blogs
March 11, 2020
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® | Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL | Earned $31.1 million in development and regulatory milestone p…
November 19, 2019
Pfenex to Present at the Evercore ISI HealthCONx Conference 2019
November 13, 2019
Pfenex Announces Management Change
Pfenex Frequently Asked Questions
When was Pfenex founded?
Pfenex was founded in 2009.
Who are Pfenex key executives?
Pfenex's key executives are Martin Brenner, Shawn Scranton and Patrick K. Lucy.
How many employees does Pfenex have?
Pfenex has 83 employees.
What is Pfenex revenue?
Latest Pfenex annual revenue is $50.3 m.
What is Pfenex revenue per employee?
Latest Pfenex revenue per employee is $606.3 k.
Who are Pfenex competitors?
Competitors of Pfenex include Forge Therapeutics, Endologix and CEL-SCI.
Where is Pfenex headquarters?
Pfenex headquarters is located at 10790 Roselle St, San Diego.
Where are Pfenex offices?
Pfenex has an office in San Diego.
How many offices does Pfenex have?
Pfenex has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies